Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208969
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $343,970 | $205,749 |
| General and administrative | 101,252 | 35,011 |
| Total operating expenses | 445,222 | 240,760 |
| Loss from operations | (445,222) | (240,760) |
| Non-operating income (expense), net: | ||
| Interest income | 19,508 | 24,915 |
| Interest expense | (12,197) | — |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s G&A?
- Revolution Medicines, Inc. (RVMD) reported G&A of $101.25M in Q1 2026.
- How has Revolution Medicines, Inc.'s G&A changed year-over-year?
- Revolution Medicines, Inc.'s G&A increased by 189.2% year-over-year, from $35.01M to $101.25M.
- What is the long-term trend for Revolution Medicines, Inc.'s G&A?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s G&A has grown at a 59.1% compound annual growth rate (CAGR), from $30.45M to $195.04M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Revolution Medicines, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude